{"id":"NCT01360866","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)","officialTitle":"A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10","primaryCompletion":"2017-04-18","completion":"2017-05-18","firstPosted":"2011-05-26","resultsPosted":"2018-09-17","lastUpdate":"2018-09-17"},"enrollment":2944,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder","Depression","Depressive Disorder, Major","Mood Disorders","Mental Disorders"],"interventions":[{"type":"DRUG","name":"OPC-34712","otherNames":[]},{"type":"DRUG","name":"Escitalopram","otherNames":["Lexapro"]},{"type":"DRUG","name":"Fluoxetine","otherNames":["Prozac"]},{"type":"DRUG","name":"Paroxetine CR","otherNames":["Paxil CR"]},{"type":"DRUG","name":"Sertraline","otherNames":["Zoloft"]},{"type":"DRUG","name":"Duloxetine","otherNames":["Cymbalta"]},{"type":"DRUG","name":"Venlafaxine XR","otherNames":["Effexor XR"]}],"arms":[{"label":"OPC-34712 (Brexpiprazole) and Escitalopram","type":"EXPERIMENTAL"},{"label":"OPC-34712 and Fluoxetine","type":"EXPERIMENTAL"},{"label":"OPC-34712 and Paroxetine CR","type":"EXPERIMENTAL"},{"label":"OPC-34712 and Sertraline","type":"EXPERIMENTAL"},{"label":"OPC-34712 and Duloxetine","type":"EXPERIMENTAL"},{"label":"OPC-34712 and Venlafaxine XR","type":"EXPERIMENTAL"}],"summary":"To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)","primaryOutcome":{"measure":"Adverse Events (AEs) - All Participants","timeFrame":"From screening to week 52/early termination","effectByArm":[{"arm":"Prior Placebo","deltaMin":400,"sd":null},{"arm":"Prior Brexpiprazole","deltaMin":511,"sd":null},{"arm":"Prior ADT","deltaMin":1165,"sd":null},{"arm":"Prior Seroquel","deltaMin":51,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":142,"countries":["United States","Canada","France","Germany","Hungary","Poland","Romania","Russia","Serbia","Slovakia","Ukraine"]},"refs":{"pmids":["37656180","31577867"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":516},"commonTop":["Weight Increased","Somnolence","Headache","Akathisia","Increased Appetite"]}}